A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT02410512 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

610

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
DRUG: MOXR0916, a humanized agonist anti-OX40 monoclonal antibody

Sponsor

Genentech, Inc.